A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
This research study is about a new drug, VX-670, for adults living with Myotonic Dystrophy Type 1 (DM1). The main goal is to check how safe the drug is when given at different doses, and how well it's tolerated by the body. Researchers also want to understand how the body processes the medicine and if it has any effects on the condition. Participants will be aged between 18 and 64 years. Some will receive the active drug (VX-670), while others will get a placebo (a dummy treatment). This is a standard way to test new medicines fairly. The study is divided into two parts to gather important information on both safety and initial signs of effectiveness.
Överblick
Vad handlar denna studie om?
This study is looking into a new treatment called VX-670 for a condition called Myotonic Dystrophy Type 1, often shortened to DM1. DM1 is a type of muscular dystrophy that can affect many parts of the body, including muscles. We want to understand if this new medicine is safe for people with DM1 and if it can help with the condition.
The study will involve giving participants either the new medicine, VX-670, or a 'placebo'. A placebo looks just like the real medicine but contains no active drug. This is common in medical research and helps us fairly compare the effects of the new medicine against not having it. By giving different doses, we can work out the best and safest amount of the medicine.
The information gathered from this study, especially in its early phases, helps us decide whether VX-670 could be a helpful treatment for DM1 in the future. It's an important step in developing new ways to manage this condition.
Viktiga punkter
- Tests a new medicine (VX-670) for Myotonic Dystrophy Type 1 (DM1).
- Aims to check safety and how the body handles the medicine.
- Compares VX-670 to a placebo (dummy treatment).
- Open to adults aged 18-64 with a confirmed DM1 diagnosis.
- Kräver regelbundna klinikbesök och hälsokontroller.
- Deltagande är frivilligt, och du kan dra dig ur när som helst.
Vem kan vara berättigad?
To join this study, you must have a confirmed diagnosis of Myotonic Dystrophy Type 1 (DM1). This diagnosis needs to be supported by a genetic test showing a certain change (called a CTG repeat of at least 100). Also, your symptoms of DM1 must have started when you were older than one year old. You need to be between 18 and 64 years old to take part.
There are also some reasons why you might not be able to join. For example, if you have certain other health conditions or illnesses, you might not be eligible. This is to make sure the study is as safe as possible for everyone involved and that we can clearly see the effects of the new medicine.
Your study doctor will go through all the detailed requirements with you to see if this study is a good fit. It's important to be open about your full health history.
Kan denna studie passa dig?
Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.
- Do you have a personal diagnosis of Myotonic Dystrophy Type 1 (DM1)?
- Did your DM1 symptoms appear after you were one year old?
- Do you have a genetic test result confirming DM1 with at least 100 CTG repeats?
- Är du mellan 18 och 64 år gammal?
- Do you not have any other major health conditions that might prevent you from joining a study?
Vad innebär deltagande?
If you decide to take part, you will have regular visits to the study clinic. During these visits, the study team will carry out various checks and assessments to see how you are doing. This often includes things like physical exams, blood tests, and other specific tests related to your condition. You will be given either the study medicine (VX-670) or a placebo, which you'll take as instructed by the study team.
The study has two parts. The first part will look at different single doses of the medicine, and the second part will look at giving the medicine multiple times. You will be closely monitored throughout your participation to ensure your safety and track any changes. The total length of time you'd be involved in the study will be explained in detail by the study team, including how many visits and follow-up checks you'll have.
Potentiella risker och fördelar
Platser (26)
- Stanford Neuromuscular ResearchVerifierat postnummerSan Carlos, United States
- University of Florida Clinical Research CenterVerifierat postnummerGainesville, USA
- University of Kansas Medical CenterVerifierat postnummerFairway, USA
- Boston BarnsjukhusVerifierat postnummerBoston, USA
- Washington University School of Medicine / St. Louis Children's HospitalVerifierat postnummerSt Louis, USA
- Wake Forest Baptist HealthVerifierat postnummerWinston-Salem, USA
- University of PennsylvaniaVerifierat postnummerPhiladelphia, USA
- Virginia Commonwealth University (Sanger Hall)Verifierat postnummerRichmond, USA
- Wesley Research InstituteVerifierat postnummerAuchenflower, Australia
- Neuroscience Clinical Trials Unit, Alfred BrainVerifierat postnummerMelbourne, Australien
- Universitaire Ziekenhuizen Leuven - Campus GasthuisbergVerifierat postnummerLeuven, Belgien
- Hopital de ChicoutimiVerifierat postnummerChicoutimi, Kanada
Vanliga frågor
What is Myotonic Dystrophy Type 1 (DM1)?
It's a long-term muscle disease that can cause muscle weakness and slowness, and affect other body systems, including the heart and brain.
Vad är en 'placebo'?
A placebo looks like the study medicine but doesn't contain any active drug. It helps researchers fairly compare how much the new drug helps versus not taking it.
Kommer jag att veta om jag får den riktiga medicinen eller placebo?
No, usually neither you nor the study team will know during the study. This helps ensure unbiased results.
Are there any costs involved for me?
Clinical trials generally cover all study-related medical costs. Check with the study team about travel or other expenses.
Hur länge kommer jag att vara med i studien?
The total duration of your participation, including visits and follow-ups, will be clearly explained by the study team before you join.
Hur du får reda på mer
Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.
Diskussion
Gemenskapsdiskussion
Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.